Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Brief Summary: The study will assess the change in coronary atherosclerotic disease as determined by intravascular ultrasound (IVUS) for aliskiren compared to placebo when given in addition to standard therapy in patients with coronary artery disease (CAD) and a blood pressure in the pre-hypertensive range.


Options:
A: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Aliskiren + Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Amlodipine | Arm Label: Aliskiren + Hydrochlorothiazide (HCTZ); Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Hydrochlorothiazide (HCTZ) | Arm Label: Aliskiren + Placebo for Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Placebo for Amlodipine | Arm Label: Aliskiren + Placebo for HCTZ; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Placebo for Hydrochlorothiazide (HCTZ) | Arm Label: Amlodipine + Placebo for Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine, Drug: Placebo for Aliskiren | Arm Label: HCTZ + Placebo for Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Hydrochlorothiazide (HCTZ), Drug: Placebo for Aliskiren | Arm Label: Placebo for Aliskiren + Placebo for Amlodipine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Aliskiren, Drug: Placebo for Amlodipine | Arm Label: Placebo for Aliskiren + Placebo for HCTZ; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Aliskiren, Drug: Placebo for Hydrochlorothiazide (HCTZ) | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren + Amlodipine, Aliskiren + Hydrochlorothiazide (HCTZ), Aliskiren + Placebo for Amlodipine, Aliskiren + Placebo for HCTZ | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Aliskiren + Amlodipine, Amlodipine + Placebo for Aliskiren | Intervention Type: DRUG; Name: Hydrochlorothiazide (HCTZ); Assigned to Arm(s): Aliskiren + Hydrochlorothiazide (HCTZ), HCTZ + Placebo for Aliskiren | Intervention Type: DRUG; Name: Placebo for Aliskiren; Assigned to Arm(s): Amlodipine + Placebo for Aliskiren, HCTZ + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for Amlodipine, Placebo for Aliskiren + Placebo for HCTZ | Intervention Type: DRUG; Name: Placebo for Amlodipine; Assigned to Arm(s): Aliskiren + Placebo for Amlodipine, Placebo for Aliskiren + Placebo for Amlodipine | Intervention Type: DRUG; Name: Placebo for Hydrochlorothiazide (HCTZ); Assigned to Arm(s): Aliskiren + Placebo for HCTZ, Placebo for Aliskiren + Placebo for HCTZ
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A

Answer: C